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Over the past 5 years we have tested many
human carcinogens and reference rodent
genotoxins in the mouse bone marrow
micronucleus (MN) assay. Without excep-
tion, activity has been observed at dose lev-
els below the level associated with clinical
signs oftoxicity, and most ofthe responses
were strong and evident at low absolute
dose levels. Thus, we have become accus-
tomed to conducting exploratory MN
assays on agents suspected of having car-
cinogenic activity in humans at the low
starting dose of 1 mg/kg. Within that con-
text, we became concerned when Shelby et
al. (1) reported the micronucleus results
for 49 chemicals tested earlier for rodent
carcinogenicity by the U.S. National
Toxicology Program (NTP). Only 5 ofthe
25 carcinogens tested were positive, 4 of
the 24 noncarcinogens tested were positive,
and only 1 of these 9 positive responses
exceeded by 3-fold the background
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Figure 1. Maximum-fold micronucleated poly-
chromatic erythrocyte (MPE) increase and mini-
mum positive dose for 45 agents tested in the
mouse bone marrow micronucleus assay. The
high-dose/weak effect regions are shaded. (a)
Twenty-six human carcinogens and 6 reference
genotoxins active in the MN assay (data from
Tables 1 and 2); (b) 5 of the 25 NTP carcinogens
active in the MN assay (data from Table 3); (c) 4
of the 24 NTP noncarcinogens active in the MN
assay (data from Table 3); (d) 5 NTP carcinogens
tested at a high dose but concluded to be inactive
in the MN assay (data from Table 4).
micronucleated polychromatic erythrocytes
(MPE) frequency (5.1-fold for monuron).
Further, the toxicity ofthe chemicals tested
by Shelby et al. (1) was generally low, lead-
ing to the use ofdose levels that were often
very high compared to those used in our
studies. For example, the positive assay
response reported by Shelby et al. (1) for
vitamin C was observed at a molar dose
level 1.65 x 105 higher than the dose level
at which we had observed activity for the
human cancer chemotherapeutic agent
etoposide. We therefore decided to display
and discuss our own micronucleus data,
those of other investigators for the human
carcinogens we have not studied, and those
for the NTP chemicals found positive in
the micronucleus assay by Shelby et al. (1).
Methods
The chemicals selected for analysis and the
selection criteria used are shown in Tables
1-4. The list comprises mainly agents that
we have studied over the past 5 years: six
widely studied rodent genotoxins, eight
human carcinogens, and two suspect
human carcinogens (fotemustine and
etoposide). The majority of these experi-
ments involved a single administration of
the test chemical. The standard MN assay
protocol used by Shelby et al. (1) involved
three daily intraperitoneal injections ofthe
test agent to male mice with measurements
made 24 hr after the final administration.
Maximum tolerated dose levels (MTD;
based on observing mice for 2 days follow-
ing three daily administrations) of the
chemicals were administered, extending to
19,000 prmol/kg (2,500 mg/kg) for
trichlorethylene (Table 4). Various adapta-
tions of the MN assay protocol have been
described, such as the use of single or
repeat doses of the test agent, or use of
intraperitoneal injection as opposed to oral
gavage dosing (2-5). To date, these vari-
ables have generally led to small quantita-
tive differences rather than qualitative
changes in test outcome (4). We have
therefore assumed that the major differ-
ences in assay responses evident between
the 44 agents shown in Figure 1 must
reflect differences in intrinsic genotoxicity.
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Data were abstracted as the minimum
positive dose and the maximum fold-
increase in response reported at any dose
level. Several of the chemicals shown in
Tables 1 and 2 could have been tested at
higher dose levels, therefore the maximum
fold-increases shown sometimes represent
a conservative estimate (eg., fotemustine,
chlorambucil, and procarbazine). Likewise,
the lowest active dose for one ofthe chem-
icals (urethane) has been estimated conser-
vatively from strong responses seen at the
only available dose levels tested. These two
data parameters are plotted in Figure 1
using a unified dose scale of pmole/kilo-
gram body weight. The chemicals are
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entered into Figure 1 in bands (A-D) to
aid focused discussion. Five NTP carcino-
gens reported to be negative in the MN
assay by Shelby et al. (1), but which were
tested at high dose levels, and four of
which gave some unreproducible evidence
ofactivity, are also included in this analysis
(Fig. Id). Vinyl chloride is shown in Table
1 and is plotted in Figure 1 based on a
conservative estimate ofthe dose level from
the inhalation study. The oral micronucle-
us data for benzene (6) are added to Table
1 to contrast with the intraperitoneal injec-
tion study results reported by Shelby et al.
(1).
Discussion
The established human carcinogens are, by
definition, potent human carcinogens.
This is because they were usually detected
as the result of low-statistical-power
human epidemiological studies. It is there-
fore interesting that most of these human
carcinogens also give a strong response in
the MN assay (7-9) (Table 1). This is
most evident for the alkylating chemother-
apeutic agents, but is not constrained to
them, as evidenced by the potent MN
assay activity of agents as structurally
diverse as aflatoxin, potassium arsenite,
and hexavalent chromium compounds
(Table 1). The aromatic amine carcinogens
benzene and nickel subsulfide give the
weakest responses in the MN assay, with
only phenacetin giving a weak response in
terms ofboth dose and magnitude ofeffect
(Table 1, Fig. la). The majority of the
classical genotoxins (agents such as ethyl
methanesulfonate, benzo[a]pyrene, trieth-
ylenemelamine, etc.) also give a strong
response in the MN assay (2,3), including
the six that we studied recently (Table 2,
Fig. la). It is within the context of such
carcinogen sensitivity that the mouse bone
marrow MN assay was incorporated into
regulatory guidelines for mutagenicity test-
ing (5,10).
Only five of the 25 NTP carcinogens
tested by Shelby et al. (1) gave a positive
Table 1. Mouse bone marrow micronucleus data for 24 human carcinogens and the 2 probable human
carcinogens etoposide and fotemustine
No. of Min. positive Max. fold-
Chemical doses Route dose (pmol/kg) increase Reference
Etoposide 1 IP 0.017 (0.1 mg/kg) 37.8 (29)
Vincristinea 1 IP 0.03 14 (30)
N-Mustarda 1 IP 3.2 35.5 (31)
Melphalan 2 IP 4.1 13 (32)
Thiotepa 1 IP 5.3 16.4 (33)
Aflatoxins 1 PO 10 24 (34)
Bis(chloromethyl)etherb 1 IP 12.4 2.5 (31)
Chlorambucil 1 IP 13 21.2 (35)
MeCCNU 1 PO 16 33.5 (36)
Fotemustine 1 IP 16 10.8 (37)
S-Mustard 1 IP 25 15.2 (38)
Potassium arsenite 1 IP 38 5.9 (39)
Cyclophosphamide 1 PO 38 21.8 (40)
Treosulphan 2 IP 90 20 (32)
Potassium chromate 2 IP 125 4.8 (41)
4-Aminobiphenyl 2 IP 150 22 (32)
Myleran 1 IP 160 4.7 (42)
Azathioprine 2 PO 180 12.25 (43)
Chlornaphazine 1 PO 186 8.8 (44)
Procarbazinea 1 PO 226 8 (30)
2-Naphthylamine 1 PO 700 4.5 (45)
Benzidine 3 PO 810 6.9 (45)
Nickel subsulfide 1 IP 1040 6.8 (46)
Phenacetin 2 PO 2230 2.7 (28)
Benzene 1 PO 2820 16.5 (6)
Vinyl chloride Inhalation 2820 12.5 (47)
Abbreviations: IP, intraperitoneal injection; PO, oral gavage.
aThe mixture formed by N-mustard, procarbazine, and vincristine (combined chemotherapy) is carcino-
genic to humans.
Chloromethylether wastested because the primary human carcinogen, bis(chlormethyl)ether (BCME), is
unavailable. Commercial chloromethylether contains 4% BCME. The dose-level of chloromethylether
used by Morita (31) has been adjusted for its BCME content. The minimum positive dose level for vinyl
chloride has been set conservatively atthe highest dose in thistable, thatfor benzene (6,48).
Table 2. Positive mouse bone marrow micronucleus assay data for six reference rodent genotoxins stud-
ied in this laboratory overthe past 4years
Min. positive Max. fold-
Chemical No. of doses Route dose (pmol/kg) increase Reference
DMH 1 PO 18 6.5 (40)
NOC 1 IP 20 23.8 (30)
DMBA 3 PO 58 10.4 (40)
MNU 1 PO 85 26.6 (29)
ENU 1 PO 97 35.9 (Tinwell, unpublished data)
Urethane 1 PO 670 30.7 (49)
Abbreviations: DMH, 1,2-dimethylhydrazine; NOC, nocodazole; DMBA, 7,12-dimethlybenz[a]anthracene;
MNU, N-methyl-N-nitrosourea; ENU, N-ethyl-N-nitrosourea; IP. intraperitoneal injection; PO, oral gavage.
Table 3. Positive mouse bone marrow micronucleus data forfive NTP carcino- Table 4. Negative mouse bone marrow micronucleus data forfive NTP
gens and four NTP noncarcinogens carcinogens'
No. of Min. positive Max. fold-
Chemical doses Route dose, pmol/kg increase
Carcinogens
4,4'-Methylene dianiline*2HCI 3 IP 140 1.9
4,4'-Oxydianiline 3 IP 190 2.5
Monuron(1) 3 IP 630 5.1
Dimethyl hydrogen phosphate 3 IP 4500 2.9
Benzene 3 IP 6400 3.0
Noncarcinogens
2,6-Toluene diamine 3 IP 260 2.3
Phenol(1) 3 IP 960 2.2
Ascorbic acid 3 IP 2800 2.9
Titanium dioxide 3 IP 3100 2.4
IP, intraperitoneal injection.
No.of Min. negative Max. fold-
Chemical doses Route dose (pmol/kg) increase
DEHA 3 IP 5400 1.4
(2000 mg/kg)
Benzyl acetate 3 IP 8300 1.1
(1250 mg/kg)
Cinnamyl anthranilate 3 IP 10000 2.8
(3000 mg/kg)
Melamine 3 IP 16000 1.8
(2000 mg/kg)
Trichloroethylene 3 IP 19000 1.9
(2500 mg/kg)
Abbreviations: DEHA, di(2-ethylhexyl)adipate; IP, intraperitoneal injection.
aThese five were selected because of the elevated dose levels used and
because ofthe weak and unreproducible assay responses forfour ofthem.
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response in the MN assay. These five posi-
tive responses were weak and observed at
high dose levels (Fig. Ib). Four of the 24
NTP noncarcinogens were also active in
the MN assay, showing similar levels of
weak activity to those seen for the 5 NTP
carcinogens (Fig. Ic). Ifthe NTP database
for the MN assay was the only one avail-
able, further use of the MN assay in
screening for potential rodent carcinogens
would cease.
Shelby et al. (1) noted that several of
the NTP carcinogens that were negative in
the MN assay may eventually be shown to
produce tumors in rodents by a nongeno-
toxic mechanism ofaction. If that were to
be established, the negative MN assay
responses would help define such chemi-
cals as nongenotoxic carcinogens, rather
than challenging the sensitivity ofthe MN
assay itself. The recent suggestion by
NIEHS scientists that the mouse liver car-
cinogen oxazepam probably produces
tumors by a nongenotoxic mechanism akin
to that ofphenobarbital indicates that the
concept of nongenotoxic carcinogenesis is
gaining general credibility (11). The five
NTP carcinogens shown in Table 4 and
Figure 1d are probably representative of
such nongenotoxic carcinogens. Thus,
di(2-ethylhexyl)adipate and cinnamyl
anthranilate induce peroxisomes in the
rodent liver, and the carcinogenic status of
benzyl acetate was recently reassessed when
it was found to be noncarcinogenic in a
repeat feed study (12,13). Likewise, the
bladder carcinogenicity of melamine may
have been caused indirectly by the induc-
tion of bladder calculi, and the mecha-
nism(s) of action of trichloroethylene as a
rodent carcinogen remains the subject of
debate. The inactivity in the MN assay of
such putative nongenotoxic carcinogens is
therefore probably consistent. However,
the possible presence of nongenotoxic car-
cinogens among these 25 NTP carcinogens
cannot alone explain the low sensitivity of
the MN assay in the Shelby et al. study.
This is because no strong MN assay
responses were observed in the whole
study. Thus, only a fine line separates the
unreproducible MN assay activities of the
five carcinogens shown in Figure id [con-
cluded negative by Shelby et al. (1)] from
the weak, but positive, responses for the
NTP carcinogens shown in Figure lb.
With the exception of monuron, none of
these positive reponses exceeded by three
times the concurrent control MPE fre-
quencies, and all occurred at dose levels
greater than 100 pmol/kg. This high-
dose/weak-effect region is shown in Figure
1 and is discussed later.
There is an obvious need to understand
the low carcinogen sensitivity of the MN
assay in the studies reported by Shelby et
Table5. Illustration ofthe synthesis ofdata requiredto discernthe differential hazardto humans oftwo
agents active inthe mouse bone marrowmicronucleus (BM MN) assay(MN assaydata from Tables 1 and 3)
Parameter Fotemustine Vitamin C
Chemical structure CHO P-CH-NH -C-N
C HOCH
CHO II HO o
0 CH3 0 NO
OH OH
Chemical reactivity Electrophilic Nonelectrophilic
Metabolism Possible formation of Anti-oxidant, radical scavenger
additional electrophiles
Salmonella assay +
Mouse BM MN assay
Qualitative response + +
Minimum positive dose 16 pmol/kg 2800 pmol/kg
Maximum fold-increase Nlx 3x
Souce of MN assay activity Alkylation of DNA Radical damage to DNA
following metabolic overload (?)
Carcinogenic potentialto humans +
al. (1), especially within the context ofthe
good performance of the assay with the
agents shown in Figure la. A speculative
solution to these conflicts is shown in
Figure 1 and is as follows. Certain elec-
trophilic, or potentially electrophilic,
chemicals are toxic, genotoxic, and car-
cinogenic to all species ofanimals, includ-
ing humans. The most potent of these
become evident as human carcinogens,
usually following only limited epidemiolo-
gy. Such agents are predictable as potential
genotoxins from consideration of their
chemical structures (14) and are readily
detectable as rodent genotoxins (7) and
rodent carcinogens (15). For such clearly
genotoxic chemicals, activity in the MN
assaywill probably reflect an aspect oftheir
carcinogenicity. In contrast, some chemi-
cals are relatively nontoxic and give no
obvious evidence ofgenotoxicity in vivo, or
of carcinogenicity within the first year of
dosing to rodents. If these chemicals are
administered at the maximum tolerated
dose over the lifetime of rodents, possible
evidence of nongenotoxic carcinogenicity
may be revealed. Some ofthese weaker car-
cinogens may also show weak activity as
genotoxins in vivo when tested at elevated
dose levels, but it is less clear ifsuch genet-
ic effects will relate mechanistically to their
rodent carcinogenicity (Fig. 1).
The possibility that administration of
chemicals to rodents at peri-toxic dose lev-
els may induce small "stress-related"
increases in MPE frequency is pertinent to
this discussion. The impact ofstress-related
activity in the MN assay is inevitably
greater for relatively nontoxic chemicals,
such as vitamin C, that would normally be
perceived as presenting a low hazard to
humans. It is therefore interesting that the
NTP carcinogens found positive in the
MN assay are concentrated in the high-
dose/weak-response shaded box of Figure
1. This box also contains the four false-
positive MN assay responses for the NTP
noncarcinogens vitamin C, titanium diox-
ide, phenol, and 2,6-toluenediamine. This
indicates that despite the good overall cor-
relation between carcinogenicity and activ-
ity in the MN assay, the correlation within
the gray box of Figure 1 is low. This, in
turn, suggests that these genetic activities
might reflect a stress-induced disturbance
oferythropoiesis in the test mice.
There are a few precedents for stress-
induced activity in the MN assay. Water
and food deprivation lead to small increas-
es in MPE frequency in rodents (16-18).
Similarly, increases in sister chromatid
exchange levels have been observed in mal-
nourished or pregnant humans (19-21).
Other factors such as hyperthermia
(22,23) and erythropoietin-induced ery-
thropoiesis (24,25) have also been associat-
ed with increases in MPE frequencies in
rodents. Further, methemoglobinemia
induced in rodents by exposure to aniline
(26) and spleen damage associated by their
exposure to phenylhydrazine (27) are
probably responsible for the increased inci-
dence of MPE observed in the bone mar-
row of these rodents. The implication is
that weak responses in the MN assay (less
than threefold) observed at peri-toxic dose-
levels or doses greater than approximately
100 pmol/kg should be interpreted with
caution. This caution would include eight
ofthe nine NTP positive responses report-
ed by Shelby et al. (1), together with the
weak positive response reported by Soutou
et al. (28) for the human renal carcinogen
phenacetin. The current problem is that
there are no recognized indicators of the
subtle stresses that may lead to such small
increases in MPE incidences. Equally, the
fact that food deprivation, for example,
yields an increase in MPE incidence similar
to that induced by vitamin C or titanium
dioxide is a cause of recurring concern. In
the absence of definitive indicators of
genetic stress, the usual signs of clinical
stress, such as piloerection, subdued behav-
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ior, urinary incontinence, etc., must be
used to indicate possible stress-related
activity in the MN assay.
Evaluation of genetic toxicity tests has
been in an analytical phase for the past 20
years. This phase was dominated by empir-
ical validations where correlations between
carcinogenicity and genetic toxicity were
assessed. There has been no clear conclu-
sion to these studies, partly because rodent
carcinogenicity has fragmented into several
mechanistic models during the same 20
years. In facing the contrast between the
past performance of the MN assay with
reference genotoxins and the human car-
cinogens and its performance as reported
by Shelby et al. (1), a move away from the
analytical to the synthetic/integrative
approach to data assessment has been
implied. This involves considering data
from established genetic toxicity assays
within the context of all available data for
the test chemical. This includes knowledge
of chemical structure, reactivity and me-
tabolism, the general toxicology of the
agent, and an appreciation of the magni-
tude ofany induced genetic effects and the
dose-levels at which they were elicited.
Such a synthesis of all available data
enables, for example, the potential human
hazard posed by exposure to fotemustine
or vitamin C to be objectively distin-
guished (Table 5), despite the fact that
each chemical can be described as "active
in the mouse bone marrow micronucleus
assay." A similarly integrated approach to
rodent carcinogenicity data assessment
would probably also reveal a gulf between
the potential carcinogenic hazard presented
to humans by classical rodent carcinogens
such as ethylnitrosourea and dimethylben-
zanthracene (Table 2) and most of the
NTP rodent carcinogens studied by Shelby
et al. (1).
In summary, we suggest that use ofthe
terms "rodent carcinogen" and a "micro-
nucleus-inducing agent" in isolation of
other toxicity data for the test agent should
be avoided. Rather, rodent carcinogenicity
and genotoxicity data should be presented
and discussed within the total toxicological
context available for the agent in question.
Correlations between carcinogenicity and
activity in the MN assay may exist in the
case of agents that show strong activities
for both endpoints at relatively low dose
levels. However, there may be no mecha-
nistic association between these two bio-
logical responses when they are only
observed at high dose levels and when the
responses are weak. Activity in the MN
assay may therefore only be predictive of
rodent carcinogenicity in the case of rela-
tively strong responses (less than threefold
increases over control levels) observed at
low dose levels (<100 pimol/kg).
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